Mineralocorticoid receptor antagonists and glucocorticoids differentially affect skeletal muscle inflammation and pathology in muscular dystrophy

Zachary M. Howard, …, Federica Accornero, Jill A. Rafael-Fortney


Graphical abstract

Find the latest version:

https://jci.me/159875/pdf
Mineralocorticoid Receptor Antagonists and Glucocorticoids Differentially Affect Skeletal Muscle Inflammation and Pathology in Muscular Dystrophy

Authors: Zachary M. Howard¹, Chetan K. Gomatam¹, Charles P. Rabolli¹,², Jeovanna Lowe¹, Arden B. Piepho¹, Shyam S. Bansal¹,², Federica Accornero¹,², Jill A. Rafael-Fortney¹

Affiliations:

1 Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, OH, United States.

2 Dorothy M. Davis Heart and Lung Research Institute, College of Medicine, The Ohio State University, Columbus, OH, United States.

* Correspondence to: Jill A. Rafael-Fortney, Department of Physiology & Cell Biology, College of Medicine, OSU, 390 BRT, 460 W. 12th Avenue, Columbus, OH 43210. Tel.: 614-292-7043; E-mail: rafael-fortney.1@osu.edu

Conflict-of-interest statement: The authors have declared that no conflict of interest exists.
Abstract

Mineralocorticoid receptor (MR) antagonists (MRAs) slow cardiomyopathy in Duchenne Muscular Dystrophy (DMD) patients and improve skeletal muscle pathology and function in dystrophic mice. However, glucocorticoids, known anti-inflammatory drugs, remain standard-of-care for DMD, despite substantial side effects. Exact mechanisms underlying MR signaling contribution to dystrophy are unknown. Whether MRAs affect inflammation in dystrophic muscles and how they compare to glucocorticoids is unclear.

The MRA spironolactone and glucocorticoid prednisolone were each administered for one week to dystrophic mdx mice during peak skeletal muscle necrosis to compare effects on inflammation. Both drugs reduced cytokine levels in mdx quadriceps, but prednisolone elevated diaphragm cytokines. Spironolactone did not alter myeloid populations in mdx quadriceps or diaphragms, but prednisolone increased F4/80\textsuperscript{Hi} macrophages. Both spironolactone and prednisolone reduced inflammatory gene expression in myeloid cells sorted from mdx quadriceps, while prednisolone additionally perturbed cell cycle genes. Spironolactone also repressed myeloid expression of the gene encoding fibronectin, while prednisolone increased its expression. Overall, spironolactone exhibits anti-inflammatory properties without altering leukocyte distribution within skeletal muscles while prednisolone suppresses quadriceps cytokines, but increases diaphragm cytokines and pathology. Anti-inflammatory properties of MRAs and different limb and respiratory muscle responses to glucocorticoids should be considered when optimizing treatments for DMD patients.
**Introduction**

Chronic inflammation exacerbates skeletal muscle pathology in Duchenne Muscular Dystrophy (DMD) and will likely persist even if emerging genetic therapies are successful. Inflammation is required for efficient wound healing following muscle injury (1). However, continuous cycles of skeletal myofiber necrosis and regeneration resulting from dystrophin protein absence in DMD lead to continual inflammation, dysregulate regeneration, promote fibrosis, and result in loss of ambulation in the late teens (1-4). Glucocorticoids are standard-of-care for DMD delaying loss of ambulation for an average of 3 years, but have numerous side effects including osteoporosis, cataracts, and behavioral changes that are only partially mitigated by intermittent treatment regimens (5-8). Emerging genetic medicines, including gene therapy with micro-dystrophins, may improve DMD to a less severe Becker Muscular Dystrophy, but fail to target muscle stem cells. Therefore, inflammation will likely persist even if these therapies are successful, requiring anti-inflammatory alternatives to glucocorticoids (9).

Glucocorticoids induce anti-inflammatory signaling by binding and activating glucocorticoid receptors (GR), steroid hormone receptor transcription factors in immune and non-immune cells (10). Adaptive immune cell functions, specifically subsets of T-cells and B-cells, are inhibited by glucocorticoids in numerous *in vivo* and *in vitro* models of human disease (11-15). Glucocorticoids also affect innate myeloid immune cells including dendritic cells, monocytes and macrophages, although many of these studies used *in vitro* treatments and never in the context of skeletal muscles or DMD (16-18).
Mineralocorticoid receptor (MR) antagonists (MRAs) are beneficial for numerous diseases and injuries (19). The endogenous mineralocorticoid, aldosterone, is the primary agonist for MR and is normally produced by the adrenal glands. Aldosterone is also produced by aldosterone synthase (CYP11B2) in infiltrating myeloid immune cells in dystrophic muscles (20, 21). However, endogenous glucocorticoids (cortisol, corticosterone) have high affinity for MR and are present at higher serum concentrations than aldosterone (22). Expression of 11β-HSD2, the intracellular enzyme that inactivates cortisol to promote aldosterone selectivity for MR, is also found within dystrophic skeletal muscles, indicating a role for MR in dystrophic muscles (21).

Although MRAs were originally used in renal and cardiovascular diseases as a diuretic, they also dampen pro-inflammatory cytokine signaling and enhance M2 macrophage functions that synergize to arrest fibrosis (23, 24). Myeloid cell MR knockout in various renal and cardiovascular preclinical disease models recapitulate improvements and anti-inflammatory properties observed with MRA usage, indicating a role of myeloid MR signaling in pathological states (25-28).

Clinical trial and preclinical data support MRA use to slow cardiomyopathy progression in DMD patients and mice (29-31). MRAs also improve function and pathology of dystrophic mouse limb and respiratory skeletal muscles (30, 32-36). Glucocorticoids dampen this efficacy since both drug classes compete for binding to the same receptors (34). Treatment of healthy human myotubes in vitro with MRAs or glucocorticoids in parallel results in different but overlapping gene expression profiles that indicate potential anti-inflammatory functions of MRAs in muscle tissue (37). Since MRAs are safe and effective for DMD cardiomyopathy, comparing how MRAs and
glucocorticoids affect myeloid inflammation is crucial for improving skeletal muscle treatments for DMD and for expanding the possible use of MRAs for other inflammatory diseases.

To determine how MRAs and glucocorticoids differentially affect inflammation in dystrophic tissues, we treated mdx mice short-term with the MRA spironolactone or the glucocorticoid prednisolone during peak dystrophic skeletal muscle necrosis and inflammation (38). From the treated mice, we analyzed skeletal muscle cytokine and chemokine levels, quantified myeloid cell populations in the limb and respiratory muscles, sorted myeloid cells from limb muscles for RNA sequencing (RNA-Seq), and assessed histological indicators of myofiber damage and fibrosis.

Results

*Spironolactone and prednisolone reduced chemokine and cytokine levels in dystrophic quadriceps, but prednisolone increased chemokine and cytokine levels in dystrophic diaphragms*

To compare the anti-inflammatory effects of GR agonism and MR antagonism on dystrophic muscles, we first performed unbiased assessments of cytokine and chemokine levels in muscles from dystrophin-deficient mdx mice after short-term treatment during the peak inflammatory phase (Figure 1). Proteome profiler arrays showed that short-term treatment with prednisolone, the active metabolite of the GR agonist prednisone, decreased numerous chemokines 20% or more including eotaxin (66%), CCL2 (27%), CCL4 (88%), CCL5 (77%), CCL12 (77%), CXCL1 (78%), CXCL2
Prednisolone also decreased numerous cytokines at least 20%, including TNFα (49%), IL-1α (75%), IL-1β (94%), IL-2 (33%), IL-4 (65%), IL-10 (83%), IL-12 (64%), IL-17 (76%), and TREM-1 (93%) (Figure 1A, E; Table 1).

Treatment with the MRA spironolactone resulted in reductions of a highly overlapping set of chemokines and cytokines as observed with GR agonism. Spironolactone reduced by at least 20% in mdx quadriceps most of the same chemokines as prednisolone including CCL2 (32%), CCL4 (52%), CCL12 (51%), CXCL1 (75%), CXCL2 (93%), CXCL9 (22%), and CXCL10 (41%) and additionally reduced CCL3 (74%), (Figure 1A, C; Table 1). Spironolactone treatment also reduced most of the same cytokines as prednisolone in quadriceps including TNFα (27%), IL-1β (78%), IL-2 (50%), IL-4 (62%), IL-10 (38%), IL-12 (37%), IL-17 (45%), and TREM-1 (83%), supporting highly conserved anti-inflammatory effects of spironolactone and prednisolone in dystrophic quadriceps muscles (Figure 1A, C; Table 2). Both spironolactone and prednisolone increased the cytokine IFNγ 1.2-fold compared to vehicle in mdx quadriceps (Figure 1A, C, E; Table 2). Spironolactone did not increase any quadriceps chemokines, and prednisolone only increased CXCL13 (2.0-fold) compared to vehicle (Figure 1A, C, E; Table 1).

Since quadriceps muscles continue to regenerate during the mdx mouse lifespan, we additionally conducted global cytokine and chemokine analysis on the more fibrotic diaphragm respiratory muscle from prednisolone or spironolactone-treated mdx mice. In contrast to the reductions observed in quadriceps, prednisolone-treatment substantially elevated mdx diaphragm chemokine levels (Figure 1B, F; Table 1). Only
CCL12 was reduced by prednisolone. Prednisolone increased chemokines in the diaphragm that were reduced in quadriceps including eotaxin (1.5-fold), CCL2 (1.2-fold), CCL4 (2.3-fold), CXCL1 (1.8-fold), CXCL2 (6.4-fold), CXCL9 (1.3-fold), and CXCL11 (2.7-fold), and additionally increased CCL3 (2.8-fold) and CXCL13 (1.1-fold). Cytokines that were reduced in quadriceps were also markedly elevated in prednisolone-treated mdx diaphragms, including TNFα (6.2-fold), IL-1α (1.4-fold), IL-1β (2.8-fold), IL-2 (2.0-fold), IL-4 (2.2-fold), IL-10 (1.5-fold), IL-12 (3.0-fold), IL-17 (4.9-fold), and TREM-1 (3.8-fold) (Figure 1B, F; Table 2). Prednisolone increased IFNγ (3.4-fold) in the diaphragm as well as in the quadriceps.

Spironolactone only reduced CXCL2 (22%) and CXCL11 (28%) chemokines and IL-4 (35%) cytokine in mdx diaphragms (Figure 1B, D; Table 1). Spironolactone elevated most of the same chemokines and cytokines in the diaphragm as prednisolone, although to a much lesser extent. Chemokines slightly increased by spironolactone include: eotaxin (1.1-fold), CCL2 (1.2-fold), CCL3 (1.3-fold), CCL4 (1.2-fold), CCL12 (1.2-fold), CXCL1 (1.6-fold), CXCL9 (1.3-fold), and CXCL10 (1.1-fold). Cytokines that increased modestly in spironolactone-treated mdx diaphragms were TNFα (1.1-fold), IL-1α (1.7-fold), IL-12 (1.9-fold), and TREM-1 (1.8-fold).

An ELISA for IL-1β was used to further validate cytokine array results. IL-1β levels in quadriceps soluble protein homogenates were significantly reduced with prednisolone treatment in comparison with vehicle treatment of mdx mice (10.1 pg/ml ± 1.2 vs. 17.5 pg/ml ± 1.9; P = 0.0418). IL-1β also trended lower with spironolactone treatment (13.2 pg/ml ± 1.5) to levels similar to wild-type C57 mice (12.6 pg/ml ± 1.3).
Prednisolone, but not spironolactone, altered the density and percentage of $F4/80^{\text{Hi}}$ macrophages in mdx quadriceps.

We next determined whether the overall reductions in pro-inflammatory cytokines and chemokines within quadriceps muscles due to short-term prednisolone or spironolactone treatment changed inflammation at the cellular level. Myeloid populations from quadriceps of mdx mice following spironolactone or prednisolone treatment from 3.5 to 4.5-weeks-of-age were quantified using flow cytometry and compared to vehicle-treated mdx controls. The skeletal muscle gating strategy is shown in Supplemental Figure 1A. Isotype controls are displayed in Supplemental Figure 1B. Representative flow cytometry gating dot-plots are displayed for myeloid cell (Figure 2A), neutrophil (Figure 2B), infiltrating monocyte (Figure 2C), macrophage (Figure 2D), CD206$^+$ macrophage (Figure 2E), and $F4/80^{\text{Hi}}$ macrophage (Figure 2F) populations in treated and vehicle control mdx quadriceps. The densities of myeloid cells (1753 cells/mg ± 185 vs. 2131 ± 222; $P = 0.356$), neutrophils (164 cells/mg ± 30 vs. 171 ± 16; $P = 0.859$), infiltrating monocytes (144 cells/mg ± 31 vs. 135 ± 20; $P = 0.823$), macrophages (1301 cells/mg ± 136 vs. 1647 ± 187; $P = 0.313$), CD206$^+$ macrophages (248 cells/mg ± 32 vs. 284 ± 24; $P = 0.698$), and $F4/80^{\text{Hi}}$ macrophages (445 cells/mg ± 58 vs. 554 ± 66; $P = 0.229$) were not different in spironolactone-treated mdx quadriceps relative to vehicle controls (Figure 2G). Prednisolone significantly increased the density of $F4/80^{\text{Hi}}$ macrophages (1094 cells/mg ± 210 vs. 554 ± 66; $P = 0.027$), but did not significantly change the density of myeloid cells (2578 cells/mg ± 380 vs. 2131 ± 222; $P = 0.277$), neutrophils (155 cells/mg ± 25 vs. 171 ± 16; $P = 0.655$), infiltrating monocytes (106 cells/mg ± 26 vs. 135 ± 20; $P = 0.443$), macrophages (2103
cells/mg ± 324 vs. 1647 ± 187; \( P = 0.185 \)) or CD206⁺ macrophages (451 cells/mg ± 98 vs. 284 ± 24; \( P = 0.079 \)) compared to vehicle controls.

Spironolactone treatment did not affect the percentage of myeloid cells (96.2% CD45⁺ ± 0.2 vs. 96.1% ± 0.2; \( P = 0.870 \)), or neutrophils (9.2% CD11b⁺ ± 1.3 vs. 7.6% ± 0.6; \( P = 0.281 \)), infiltrating monocytes (7.6% CD11b⁺ ± 1.1 vs. 6.7% ± 0.9; \( P = 0.534 \)), macrophages (75.0% CD11b⁺ ± 2.5 vs. 76.8% ± 1.9; \( P = 0.559 \)) as a percentage of total myeloid cells, or CD206⁺ macrophages (19.8% CD64⁺ ± 1.9 vs. 17.9% ± 1.4; \( P = 0.436 \)), or F4/80⁺ hi macrophages (33.7% CD64⁺ ± 1.8 vs. 35.6% ± 2.4; \( P = 0.553 \)) within \textit{mdx} quadriceps relative to vehicle controls (Figure 2H). Prednisolone significantly and substantially increased the percentage F4/80⁺ hi macrophages (49.6% CD64 ± 2.6 vs. 35.6% ± 2.4; \( P < 0.001 \)) compared to vehicle controls. Prednisolone also mildly, but significantly, increased the percentage of myeloid cells (97.4% CD45⁺ ± 0.3 vs. 96.1% ± 0.2; \( P < 0.001 \)). Prednisolone treatment did not significantly change the percentages of neutrophils (6.5% CD11b⁺ ± 0.9 vs. 7.6% ± 0.6; \( P = 0.440 \)), infiltrating monocytes (4.0% CD11b⁺ ± 0.9 vs. 6.7% ± 0.9; \( P = 0.067 \)), macrophages (81.6% CD11b⁺ ± 1.9 vs. 76.8% ± 1.9; \( P = 0.128 \)) or CD206⁺ macrophages (20.2% CD64⁺ ± 1.7 vs. 17.9% ± 1.4; \( P = 0.345 \)) in quadriceps muscles relative to vehicle-treated \textit{mdx} controls. All myeloid populations represented as the percentage of total CD45⁺ cells were also calculated (Supplemental Figure 2B). An association between CD206 and F4/80⁺ hi macrophage surface markers was found and represented in a t-distributed Stochastic Neighbor Embedding (tSNE) plot; 69.2% ± 1.5 of vehicle-treated \textit{mdx} quadriceps CD206⁺ macrophages were F4/80⁺ hi and 38.6% ± 2.8 of F4/80⁺ hi macrophages were CD206⁺ (Supplemental Figure 2A).
**Prednisolone, but not spironolactone, altered the percentage of F4/80\(^{\text{Hi}}\) macrophages in mdx diaphragms.**

We next quantified myeloid cells from diaphragms of spironolactone or prednisolone-treated *mdx* mice as done for quadriceps-derived cells. The representative flow cytometry gating dot-plots are shown for myeloid cell (Figure 3A), neutrophil (Figure 3B), infiltrating monocyte (Figure 3C), macrophage (Figure 3D), CD206\(^{+}\) macrophage (Figure 3E), and F4/80\(^{\text{Hi}}\) macrophage (Figure 3F) populations in treated and vehicle control *mdx* diaphragms. The density of myeloid cells (614 cells/mg ± 126 vs. 879 ± 209; \(P = 0.287\)), neutrophils (104 cells/mg ± 21 vs. 78 ± 14; \(P = 0.421\)), infiltrating monocytes (71 ± 20 vs. 57 ± 16; \(P = 0.543\)), macrophages (347 cells/mg ± 81 vs. 542 ± 124; \(P = 0.208\)), CD206\(^{+}\) macrophages (34 cells/mg ± 6 vs. 50 ± 10; \(P = 0.172\)) and F4/80\(^{\text{Hi}}\) macrophages (28 ± 4 vs. 61 ± 13; \(P = 0.070\)) were not significantly different in spironolactone-treated *mdx* diaphragms compared to vehicle controls (Figure 3G). Prednisolone treatment did not significantly shift the diaphragm densities of myeloid cells (479 cells/mg ± 165 vs. 879 ± 209; \(P = 0.116\)), neutrophils (84 cells/mg ± 26 vs. 78 ± 14; \(P = 0.842\)), infiltrating monocytes (28 cells/mg ± 9 vs. 57 ± 16; \(P = 0.221\)), macrophages (275 cells/mg ± 105 vs. 542 ± 124; \(P = 0.092\)), CD206\(^{+}\) macrophages (28 cells/mg ± 7 vs. 50 ± 10; \(P = 0.070\)) or F4/80\(^{\text{Hi}}\) macrophages (42 cells/mg ± 17 vs. 61 ± 13; \(P = 0.382\)) compared to vehicle-treated *mdx* mice.

Similar to quadriceps, treatment with spironolactone did not significantly change the percentage of diaphragm myeloid cells (88.9% CD45\(^{+}\) ± 0.6 vs. 87.4% ± 1.1; \(P = 0.369\)), or neutrophils (18.0% CD11b\(^{+}\) ± 3.0 vs. 12.5% ± 1.2; \(P = 0.128\)), infiltrating monocytes (10.8% CD11b\(^{+}\) ± 1.5 vs. 9.3% ± 1.5; \(P = 0.447\)) or macrophages (56.1%...
CD11b+ ± 3.7 vs. 61.0% ± 3.1; P = 0.374) as a percentage of total myeloid cells, or CD206+ macrophages (10.7% CD64+ ± 1.2 vs. 10.3% ± 1.3; P = 0.851), or F4/80Hi macrophages (9.0% CD64+ ± 1.0 vs. 9.7% ± 1.4; P = 0.679) in mdx diaphragms relative to vehicle-treated controls (Figure 3H).

Prednisolone significantly increased percentages of myeloid cells (93.1% CD45+ ± 1.4 vs. 87.4% ± 1.1; P = 0.002) and F4/80Hi macrophages (15.7% CD64+ ± 2.1 vs. 9.7% ± 1.4; P = 0.043) in mdx diaphragms relative to vehicle controls. Neutrophil (18.9% CD11b+ ± 2.7 vs. 12.5% ± 1.2; P = 0.082), infiltrating monocyte (5.8% CD11b+ ± 0.8 vs. 9.3% ± 1.5; P = 0.073), macrophage (56.0% CD11b+ ± 4.4 vs. 61.0% ± 3.1; P = 0.371) and CD206+ macrophage (13.0% CD64+ ± 1.9 vs. 10.3% ± 1.3; P = 0.211) percentages were not significantly affected by prednisolone treatment in mdx diaphragms. All diaphragm myeloid populations represented as the percentage of total CD45+ cells were also calculated (Supplemental Figure 2C). Similar to the observation in quadriceps, the macrophage association between CD206 and F4/80Hi was also found in diaphragm. Macrophages positive for CD206 were 35.4% ± 1.8 F4/80Hi while 47% ± 7.2 of macrophages displaying F4/80Hi were CD206+ (Supplemental Figure 2A).

Prednisolone and spironolactone have contrasting effects on molecular signatures of myeloid cells in dystrophic muscles.

Since dystrophic quadriceps muscle cytokine levels were reduced similarly by both prednisolone and spironolactone, but myeloid cell populations were changed only by prednisolone, we next determined how each drug affects the molecular signatures of
skeletal muscle myeloid cells. RNA was isolated from myeloid cells after fluorescently activated cell sorting (FACS) from spironolactone-, prednisolone-, or vehicle-treated *mdx* quadriceps muscles using the same one-week treatment regimen as for the flow cytometry experiments. Myeloid cell gene expression signatures from prednisolone and spironolactone treated mice were different from each other and from vehicle-treated *mdx* mice (*Figure 4A, B, C*). Indeed, principal component analysis (PCA) revealed clear separation between vehicle and each of the treatments (*Figure 4A*). The differential impact that each of the treatments had on gene expression in myeloid cells is further highlighted by global visualization of all differentially regulated transcripts (*Figure 4B* and **Supplemental Table 1, Supplemental Table 2**). 686 and 263 genes were differentially expressed due to prednisolone and spironolactone respectively with only 53 genes shared between treatments (*Figure 4C, Supplemental Figure 3A-C*). Gene ontology analysis of *mdx* quadriceps myeloid cell biological processes affected by spironolactone and prednisolone also indicate the treatment effects differ substantially (*Figure 4D*). Prednisolone affected numerous signaling pathways involved in mitosis, including assembly of the actomyosin contractile ring and the mitotic spindle. Additionally, prednisolone affected genes associated with the biological categories of cell-cell adhesion, natural killer cell chemotaxis, apoptotic signaling in B cells, and responses to IL-13. Spironolactone predominantly changed pathways associated with IL-18 expression, NK cell chemotaxis, T_{H}17 cell differentiation, histone H3-K27 demethylation, p38MAPK, transcriptional hypoxic response (primarily via VEGFA and HIF1a), and B-1 B cell homeostasis (*Figure 4D*). Gene ontology analysis of molecular
functions changed from prednisolone or spironolactone treatment as well (Supplemental Figure 3D).

Despite the clear distinction in gene signature affected by spironolactone and prednisone on dystrophic myeloid cells, a significant overlap is observed with the 53 genes regulated by both treatments (Figure 4C, 5A, 5B, Supplemental Figure 3C). Spironolactone and prednisolone treatment reduced myeloid cell expression of thrombospondin-1 (THBS1), an adhesive glycoprotein involved in angiogenesis. Additionally, decreases in the expression of Fos, a subunit of transcription factor AP-1, were observed with both treatments. Chemokine expression was also reduced by spironolactone and prednisolone treatment, including Ccl3. Reduction of Ccl3 expression in both treatment groups validates that at least some of the reduced levels observed in the cytokine/chemokine assays of treated quadriceps muscles are due to transcriptional regulation in myeloid cells, although discrepancies between myeloid cell expression and whole-muscle protein levels are observed. Both treatments also reduced the expression of Dual Specificity Phosphatase (Dusp) 1, a known regulator of cytokine expression and macrophage activity (39). DUSP1 is known to regulate vascular endothelial growth factor A (VEGFA), which is also reduced by both treatments (40). Mdx quadriceps myeloid cell expression of Atp2a1, or SERCA1, was upregulated in both spironolactone- and prednisolone-treated mdx mice, although this is likely a more relevant change if it also occurs in muscle fibers. Additionally, Fms Related Receptor Tyrosine Kinase 3 (Flt3) expression was upregulated by both treatments. Mdx quadriceps myeloid cell expression of Hif1a was reduced by spironolactone yet increased by prednisolone treatment. Most relevant for pathology, expression of Fn1
encoding the ECM component fibronectin was reduced by spironolactone but increased by prednisolone.

*Spironolactone, but not prednisolone leads to a reduced amount of fibronectin in diaphragm after 1 week in dystrophic mice.*

The presence of high levels of *Fn1* gene expression in myeloid cells was a surprise, as was its reduction by spironolactone and increase by prednisolone treatment. To determine whether these differences in myeloid *Fn1* translated to changes in dystrophic fibrosis after such a short treatment, localization of the *Fn1* gene product, extracellular matrix protein fibronectin, was assessed in dystrophic diaphragm. Since diaphragm develops more severe fibrosis than quadriceps in dystrophic mice and at a much earlier time-point (41), and RNA sequencing of myeloid cells isolated from the very small diaphragm tissue would be technically challenging requiring pooling very large numbers of mice, the effects on diaphragm pathology are critical to investigate.

After one week of treatment, overall *mdx* diaphragm morphology appeared qualitatively improved by spironolactone treatment but worsened by prednisolone ([Figure 6A](#)). The number of actively degenerating myofibers (lgG⁺) per 10 µm² was not significantly different in *mdx* diaphragms following one week of either spironolactone (1.0 IgG⁺/10 µm² ± 0.6 vs. 3.4 ± 1.8; *P* = 0.419) or prednisolone (10.3 IgG⁺/10 µm² ± 4.1 vs. 3.4 ± 1.8; *P* = 0.289) treatment relative to vehicle controls ([Figure 6B](#)). However, spironolactone treatment significantly reduces fibrosis (8.0% fibronectin ± 1.1 vs. 16.4% ± 2.4; *P* = 0.019), whereas prednisolone-treated diaphragms are not different (14.7% fibronectin ± 3.5 vs. 16.4% ± 2.4; *P* = 0.905) from *mdx* vehicle controls ([Figure 6C](#)).
Despite the small amount of replacement fibrosis present in *mdx* quadriceps compared to diaphragm, 2 weeks of prednisolone treatment was sufficient to worsen pathology (Figure 6D) and significantly increase fibrosis compared to vehicle controls (13.7% fibronectin ± 1.7 vs. 3.0% ± 0.7; *P* = 0.004) (Figure 6E). Spironolactone-treated quadriceps were not different relative to vehicle controls (5.2% fibronectin ± 0.9 vs. 3.0% ± 0.7; *P* = 0.136). Large areas of injury containing fibrotic replacement of muscle in prednisolone-treated quadriceps contained infiltration of a mixture of fibroblasts and myeloid inflammatory cells (Figure 6D).

**Discussion**

In this study, dystrophic (*mdx*) mice were treated with spironolactone or prednisolone during peak skeletal muscle necrosis to delineate the systemic anti-inflammatory properties of MRAs and glucocorticoids in dystrophic muscles. Determining the impact of MRAs on dystrophic skeletal muscle inflammation is critical for optimizing therapies for DMD and other muscular dystrophies, as well as identifying new indications for MRA use. Despite its use as standard-of-care therapy, minimal information exists about how prednisone dampens myeloid inflammation in dystrophic muscles. Since glucocorticoids bind MR and dampen MRA efficacy, comparing how these drugs affect *mdx* limb and respiratory muscle inflammation is necessary for ultimately improving patient outcomes with corticosteroids.

Chemokine and cytokine protein levels were similarly reduced in *mdx* quadriceps muscles by both spironolactone and prednisolone treatment. This data was consistent
with an ELISA for IL-1β and with reduced transcription of genes encoding TNFα, CCL3 and CCL4 in isolated myeloid cells from spironolactone treated *mdx* mice. However, there was a dramatic increase of almost all diaphragm chemokines and cytokines in prednisolone-treated *mdx* mice. Upregulation of both pro-inflammatory and anti-inflammatory cytokines support crosstalk to regulate skeletal muscle healing. Prednisolone is likely a more potent immunosuppressant than spironolactone, which may inhibit necessary diaphragm inflammation and paradoxically manifest in the production of more chemokines and cytokines. While inhibiting exogenous inflammation may be beneficial in dystrophic limb skeletal muscle, impeding monocyte recruitment to dystrophic diaphragms could hinder the immune-mediated regenerative response. Splenectomies to reduce muscle infiltrating monocytes in *mdx* mice performed before disease onset reduces myofiber degeneration and inflammation but performed after disease onset increases pathology because monocytes are essential for efficient limb muscle regeneration (42). The *mdx* diaphragm may be even more susceptible to potent immunosuppression because of inherent immunological differences relative to limb muscle (43, 44). However, results from the proteome profiler will need to be validated in the future for each individual cytokine or chemokine to test more specific hypotheses relevant to the function of these inflammatory molecules.

Spironolactone treatment did not significantly change the density or percentages of numerous myeloid populations quantified in *mdx* skeletal muscle, however treatment reduced fibrosis in *mdx* diaphragms. *Fn1* encoding fibronectin is one of the highest expressing genes in the CD45+ CD11b+ population that is repressed by spironolactone, supporting that the anti-fibrotic activity of MR antagonism may be acting directly through
macrophages rather than only fibroblasts. In contrast, Fn1 is surprisingly increased by prednisolone. Thbs1 encoding the fibronectin-binding protein thrombospondin-1 was reduced by both spironolactone and prednisolone. Expression of Thbs1 is positively correlated with disease severity, including reduced length of ambulation, in DMD patients (45). Fibronectin is a soluble, extracellular matrix protein elevated in muscular dystrophy, facilitating satellite cell expansion, immune cell invasion and adhesion, and fibroblast pro-inflammatory activity (46-48). Although fibrocytes are known to express numerous ECM genes, they express low levels of fibronectin (49). Therefore, these data support the novel observation that myeloid cells may contribute a major source of fibronectin, which is a major component of fibrotic tissue in dystrophic muscles and that MR antagonism represses this fibrotic pathway. This change in quadriceps muscles suggest that fibronectin activity may represent a very early pathogenic step in fibrosis, since these muscles do not become nearly as fibrotic as diaphragm muscles. One week-of spironolactone, but not prednisolone treatment, significantly reduces fibronectin localization in mdx diaphragms further supporting the anti-fibrotic effect of spironolactone on multiple muscle types. Although it was known that daily treatment of dystrophic mice with prednisolone exacerbates, while spironolactone improves muscle pathology over time, the short-term effects of both treatments had not been previously investigated.

We have previously observed myofiber membrane-stabilizing effects of spironolactone (50, 51). Numerous pathways involved in membrane stabilization, including basal lamina and extracellular matrix components conferring compression resistance and tensile strength, were increased from spironolactone treatment. Basal
lamina genes include $Lamb1$, $Col4a1$ and $Col4a2$. Other gene encoding proteins known to interact in ECM environments include: $Dcn$, $Sparc$, $Sparcl1$, $Fbn2$, $Thbs3$ and $Pxdn$. Investigation of whether spironolactone also causes myofibers to upregulate these genes will need to be investigated. It is possible that myeloid cells may have the capacity to reinforce the microenvironment surrounding individual myofibers with ECM in a paracrine manner, while simultaneously inducing fibroblasts to function similarly (52).

Prednisolone treatment increased the percentages of myeloid cells and $F4/80^{\text{hi}}$ macrophages in both quadriceps and diaphragms. These results align with the well-documented, potent immunosuppressive effects of leukocyte glucocorticoid signaling. Increases in $F4/80^{\text{hi}}$ macrophages via intramuscular injection enhance regeneration following ischemia-reperfusion skeletal muscle injury (53). Diaphragms appear unable to expand the significantly smaller $F4/80^{\text{hi}}$ macrophage population to the extent of the quadriceps, which may be detrimental to pathology since mouse diaphragm resident macrophages express more stress-response elements while resident macrophages in quadriceps are more M2-like (43). Other groups have observed decreases in $mdx$ skeletal muscle $F4/80$ macrophages by immunohistochemistry from glucocorticoid treatment, which may be explained by study differences in the route of drug administration, treatment time-course, and method of measurement (8). One limitation of interpreting this data is that markers for every immune cell population are not included in the flow cytometry panels and small amounts of these cells may be included in some of the gates. For example, muscle-infiltrated eosinophils were not analyzed but express $F4/80$ and possibly CD64. Additionally, circulating monocytes are known to
increase cell surface levels of CD64 when stimulated with inflammatory cytokines (54). Fibrocytes are also CD11b+ and LY6C+ (49).

Expression of Fos (AP-1), Dusp1 and Vegfa were downregulated by both spironolactone and prednisolone treatment in mdx quadriceps myeloid cells. Dusp1 and Fos are 2 of the 4 highest expressing genes in muscle myeloid cells that are repressed by spironolactone. Expression of both genes is known to confer resistance to tyrosine kinase inhibitors in myeloid leukemia, promoting cancerous cell growth (55). Activation of AP-1 signaling is also important for myeloid cell differentiation and survival in the presence of inflammatory cytokines, such as IL-6 (56). In addition, myogenesis is regulated by AP-1 signaling, and pharmacological inhibition of AP-1 prevents muscle wasting in models of cancer cachexia (57, 58). Overall, increasing VEGFA is being broadly discussed as a therapeutic option for DMD patients to increase angiogenesis and satellite cell activity, however, its efficacy is unknown (59, 60). In contrast, another study demonstrated that chronic Vegfa expression dysregulates angiogenesis, induces fibrosis, and promotes macrophage accumulation in ischemic rat hindlimb muscles (61).

Other genes significantly changed by spironolactone and prednisolone are less likely to be biological relevant in myeloid cells, but similar increases in other cell types should be investigated. Expression of Atp2a1 (SERCA1) was upregulated by both spironolactone and prednisolone in mdx quadriceps myeloid cells. Overexpression of SERCA1 in dystrophic mice reduces pathology by improving intracellular Ca\textsuperscript{2+} control, enabling more efficient sarcoplasmic reticulum uptake and thereby lowering total cytosolic Ca\textsuperscript{2+} (62, 63). Hif1a is another of the eight genes differentially affected by spironolactone and prednisolone. Chronic hypoxic signaling induces over-activation of
fibroblasts in dystrophic skeletal muscle, and inhibitors of hypoxia-inducible factors (HIFs) accelerate recovery following limb injury in mice (64, 65).

Numerous biological processes were affected by prednisolone treatment, including mitosis, cell adhesion, NK cell chemotaxis and IL-13 immune responses. GR has been found to co-localize with mitotic spindles, and knockdown of GR renders mitosis dysfunctional, interfering with chromosome separation and causing cell death (66). Glucocorticoids are also known to induce induction of apoptosis in healthy and malignant human B cells, suggesting they may also influence myeloid cell survival (67).

Spironolactone repressed Dusp1, Dusp5 and Dusp10, which encode phosphatases that negatively regulate mitogen activated protein kinases that are involved in a plethora of inflammatory responses in macrophages, including production of pro-inflammatory mediators and apoptosis (68). If p38MAPK signaling is activating apoptosis in mdx quadriceps myeloid cells, downregulation of the phosphatase DUSP1 may decrease detrimental inflammation. Indeed, muscle-specific knockout of Mapk14, the gene encoding p38α, in the mdx mouse results in amelioration of pathology by preventing B cell leukemia 2 (Bcl-2)-mediated myofiber death (69).

The experiment to identify gene expression changes in dystrophic myeloid cells downstream from glucocorticoid or MRA treatment was specifically designed to assess initial differences before the entire microenvironment had changed due to treatment effects on other cell types and should be interpreted under these limitations. Previous studies of gene expression within entire muscles after 2 weeks or 16 weeks of treatment can be used to compare with this data, to identify acute versus chronic effects and begin to dissect gene expression effects on other cell types (21, 50).
Short-term treatment with spironolactone and prednisolone changed numerous parameters of inflammation and pathology in *mdx* mice. While prednisolone appears to be the more potent immunosuppressant, spironolactone has moderate anti-inflammatory properties that may temper excessive inflammation without interfering with efficient regeneration in both limb and respiratory skeletal muscles. Long term MRA treatment leads to improved diaphragm and limb muscle function and pathology in dystrophic mice (30, 33, 36). However, a complete knockout of myeloid MR on an *mdx* background leads to higher cytokine and chemokine levels in quadriceps and increased diaphragm fibrosis, suggesting cross-talk between inflammatory cells and other cell types within the dystrophic skeletal muscle microenvironment (70). Inflammatory cells play a known role in promoting regeneration and repair, therefore complete abrogation of their injury response can lead to long term deleterious consequences that may underlie the observed side effects by prednisolone. Moreover, glucocorticoids have recently been demonstrated to induce pro-adipogenic effects under conditions of upregulated cAMP signaling, which will spatially and temporally occur in dystrophic skeletal muscle (71, 72).

Histological analysis after short-term treatment was used to validate tissue level effects due to gene expression changes in fibronectin. Several previous studies demonstrate that *mdx* mice treated daily with prednisolone exhibit more severe cardiac and skeletal muscle pathology (34, 73, 74). However, more recent studies support beneficial effects from weekly dosing in dystrophic mice and patients (8, 75). Another study where *mdx* mice were treated with prednisolone earlier from 2 to 4 weeks-of-age, identified decreased expression of cellular adhesion molecules, and also showed an
improvement in myofiber degeneration (76). Since prednisolone and spironolactone compete for GR and MR binding and reduce the efficacy of each other, and GR agonism and MR antagonism lead to similar overall anti-inflammatory changes, alternating administration of the two drugs could be investigated for improved efficacy in future studies.

Methods

Mouse treatments. Mdx mice were treated using water bottles containing 250 mg/L spironolactone (SPR) (Sigma-Aldrich, St. Louis, MO; S3378) or 6.7 mg/L prednisolone (PRD) (Sigma-Aldrich, St. Louis, MO; P6004), the active metabolite of prednisone dissolved in MediDrop containing sucralose (Clear H₂O, 75-01-1001, Westbrook, ME). Mice were treated during the peak of inflammation for 10 days for cytokine and chemokine level analysis to allow detection of differences in protein expression (4 to 5.5 weeks-of-age), for 7 days (3.5 to 4.5 weeks-of-age) for flow cytometry, RNA Sequencing and diaphragm immunohistochemistry or for 14 days (3.5 to 5.5 weeks of age) for quadriceps immunohistochemistry and histology. Approximate dosages for spironolactone and prednisolone treatment were 37.5 and 1 mg/kg × day, respectively (8, 33). mdx mice given MediDrop vehicle (VEH) were used as controls for all experiments. Mice were housed 5 per cage and euthanized via cervical dislocation.

Skeletal muscle protein isolation, cytokine proteome arrays and ELISA. Isolation of protein from mdx skeletal muscle was performed as previously described (44). In brief, 5.5-week-old mdx quadriceps and diaphragms dissected from treated and control mice
[n: VEH = (2M, 3F); SPR = (2M, 3F); PRD = (2M, 2F)] for cytokine array analysis and half of each quadriceps from a second cohort of 5.5-week-old mdx mice dissected from 2 week-treated or control mice [n: VEH = (4M, 1F); SPR = (4M, 1F); PRD = (4M); C57 = (2M, 1F)] for ELISA were flash-frozen in liquid nitrogen and homogenized in manufacturer-recommended lysis buffer containing protease inhibitors. Following protein isolation, sample concentrations were measured using the DC protein assay (Bio-Rad Laboratories, Hercules, CA; 5000166). Array membranes from Proteome Profiler Mouse Cytokine Array Kit A (R&D Systems, Minneapolis, MN; ARY006) were incubated with 5 mg of protein pooled from all samples from each treatment group and muscle. The assay was completed according to the manufacturer's instructions in duplicate and pixel densitometry was performed on the blot films using HL Image++ Quick Spots Tool version 25.0.0r (Western Vision Software, Salt Lake City, UT).

Soluble protein homogenates isolated from quadriceps from mdx mice treated for 2 weeks or controls, were used to perform a standardized enzyme link immunosorbent assay (ELISA) in duplicate for the detection of inflammatory cytokine IL-1β/IL-1F2 according to the manufacturer's instructions (R&D Systems, Minneapolis, MN; MLB00C). ELISA results were quantified by absorbance at 450 nm on a microplate reader (SpectraMax M4, Molecular Devices, CA).

Generation of single-cell suspensions from skeletal muscles. Single-cell suspensions were generated from treated 4.5-week-old mdx quadriceps and diaphragms for flow cytometric analysis of immune cells as previously described (44). Briefly, quadriceps and diaphragms [n: VEH = (5M, 7F); SPR = (5M, 8F); PRD = (6M, 7F)] were dissected, rinsed in cold DPBS, and finely minced with razor blades. Diaphragms were pooled
from 2 mice for each replicate. Pairs of quadriceps from each individual mouse were analyzed independently. Following dissociation, muscles were digested with 10 mL/g of digestion buffer comprised of DMEM (ThermoFisher, Waltham, MA; 11995-065), 0.02% Collagenase P (Roche, Basel, Switzerland; 11213857001), and 0.1% RQ1 DNase (Promega, Madison, WI; M6101) in a 37 °C water bath for 30 minutes. After muscle digestion, the resulting suspension was passed through a 70 µm filter then a 40 µm filter. Cells were fixed in 1% paraformaldehyde on ice for 10 minutes. All single cell suspensions were kept at 4 °C following fixation for up to 3 days before staining for flow cytometry. Cells for flow sorting were left unfixed, stained and sorted immediately.

Flow cytometric analysis of skeletal muscle immune cells. Flow cytometry antibodies utilized for staining were as follows: CD45 (phycoerythrin-Cy7; Thermo Fisher, Waltham, MA; 25045182), CD11b (allophycocyanin; Biolegend, San Diego, CA; 101212), LY6G (allophycocyanin/FIRE750; Biolegend, San Diego, CA; 127652), LY6C (eFluor450; Thermo Fisher, Waltham, MA; 48593282), CD64 (BV605; Biolegend, San Diego, CA; 139323), MHC II (BV650; Biolegend; 107639), CD206 (peridinin-chlorophyll-protein (PerCP)-eFluor710; Thermo Fisher, Waltham, MA; 46206182) and F4/80 (fluorescein isothiocyanate; Biolegend; 123108). The markers were used to identify leukocytes (CD45+), myeloid cells (CD45+ CD11b+), neutrophils (CD45+ CD11b+ LY6G+), infiltrating monocytes (CD45+ CD11b+ LY6G- CD64- LY6CHi), macrophages (CD45+ CD11b+ LY6G- CD64+), CD206+ macrophages (CD45+ CD11b+ LY6G- CD64+ CD206+), and F4/80Hi macrophages (CD45+ CD11b+ LY6G- CD64+ F4/80Hi) in the mdx quadriceps and diaphragms single cell suspensions. Corresponding isotype controls were included in all experiments. Cells were permeabilized prior to CD206 staining.
using DPBS-solubilized 0.5% Tween-20 (Sigma-Aldrich, St. Louis, MO; P1379).

Experiments were performed using a Becton Dickinson LSRFortessa Flow Cytometer (Becton Dickinson, Franklin Lakes, NJ) and data was analyzed with FlowJo software version 10.7.1 (Becton Dickinson).

Fluorescently activated cell sorting (FACS) and RNA isolation. Single cell suspensions were prepared from quadriceps as described above from 4.5-week-old mdx mice treated with spironolactone, prednisolone, or vehicle for 7 days [n: VEH = (4M, 5F); SPR = (4M, 5F); PRD = (3M, 6F)]. Cells from 3 pairs of mdx quadriceps were pooled for each biological replicate. Freshly isolated unfixed cells were extracellularly stained with CD45 (PE-Cy7; ThermoFisher, 25045182) and CD11b (APC; Biolegend, 101212) as described above and the CD45^+ CD11b^+ myeloid cells were isolated using a Becton Dickinson FACSaria III. UltraComp eBeads (ThermoFisher, 01222242) were used as single-color controls for compensation in real time. Directly following FACS, RNA was isolated from the myeloid cells using a NucleoSpin RNA XS kit (Takara, 740902) according to the manufacturer’s instructions. Live versus dead cells were not distinguished.

RNA Sequencing – RNA Sequencing was performed as previously described (77). RNA was shipped for library preparation (DNBseq-G400 sequencing, transcriptome library, BGI Americas) and RNA Sequencing (Complete Genomics, BGI Americas). Fastq files were checked for quality using FASTQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Processed fastq files were aligned using Hisat2 (78) against the UCSC mm39 mouse genome (https://hgdownload.soe.ucsc.edu/goldenPath/mm39/bigZips/). Aligned files were sorted
using Samtools (79) and were then used as input to generate count matrices using HTSeq (80). GTF files matched to UCSC mm39 were used as the HTSeq index. HTSeq count matrices were combined and analyzed for differential expression using DESeq2 (81) with a Benjamini-Hochberg adjusted \( p \)-value less than 0.05. All sequencing data are publicly available through NIH Gene Expression Omnibus (Accession Number: GSE197553). PCA plot was generated from DESeq2 and heatmaps were generated using the ‘pheatmap’ package in R. Heatmaps were produced using normalized read counts to calculate Z-scores. Plotted transcripts are those that are significantly enriched in their respective categories by DESeq2 (Adjusted \( p \) value < 0.05). Gene Ontology analysis was performed on differentially expressed transcripts using the WEB-based gene set analysis toolkit (WebGestalt) (82). Overrepresentation analysis was performed to analyze transcripts enriched in prednisolone or spironolactone treated animals. The background was set to protein coding transcripts. Categories were selected with an FDR value < 0.05, with the minimum number of genes per category set to 10 and the maximum number of genes per category set to 2000.

**Overlapping Gene Significance.** Significance of the overlapping 53 genes was determined by randomly selecting 686 genes (total number of significantly altered genes in Prednisolone treatment) from the total 50559 genes which were sequenced. This randomly selected pool of 686 genes was then compared to the significantly altered 263 genes found in Spironolactone, and the overlap was calculated. This process was simulated 1000 times to generate a Poisson distribution to fit the simulated data (Supplemental Figure 2A, B, C). A Goodness-of-Fit test was performed to confirm that the simulated data could be sufficiently modeled by the Poisson distribution. A test
mean at the hypothesized value of 53 was then compared to the fitted Poisson distribution to test significance. Simulation was performed using R version 4.1.2. Statistical tests were performed in JMP Pro 15.2.0 (SAS Institute).

**Histology and immunofluorescence analysis.** Diaphragms and quadriceps were isolated from 4.5-week-old *mdx* mice \([n: \text{VEH} = (3M, 5F); \text{SPR} = (3M, 4F); \text{PRD} = (3M, 4F)]\), and 5.5-week-old *mdx* mice \([n: \text{VEH} = (4M, 2F); \text{SPR} = (4M, 2F); \text{PRD} = (4M, 2F)]\) respectively; treated with spironolactone, prednisolone, or vehicle as described above and embedded in optimal cutting compound, frozen on liquid nitrogen-cooled isopentane and cut into 8 µm sections on a cryostat (Bright, Huntingdon, UK). Quality control of sections was performed by hematoxylin and eosin staining for overall histology. Immunofluorescence was performed with 1:100 AlexaFluor-488-conjugated goat-anti-mouse IgG antibody (Invitrogen, Waltham, MA; A11029) to detect endogenous IgG and with 1:40 rabbit anti-mouse fibronectin primary antibody (Abcam, Cambridge, MA; 23750) and 1:200 AlexaFluor-555-conjugated goat anti-rabbit secondary antibody (Invitrogen, Waltham, MA; A21429). For fibroblast and myeloid immune cell immunofluorescence colocalization, the sections were incubated with 1:50 rat anti-mouse monoclonal CD11b antibody (BD Pharmigen #550282) and 1:600 rabbit anti-mouse polyclonal vimentin antibody (Abcam #ab45939) and then incubated with 1:200 AlexaFluor-488-conjugated chicken anti-rat (Life Technologies A-21470) and 1:200 AlexaFluor-555-conjugated goat anti-rabbit (Invitrogen #A21429) secondary antibodies. Composite images were taken on a Nikon Eclipse 800 microscope under a 10x objective using a Nikon DS-Ri2 camera driven by Nikon Br Elements software (Melville,
NY). The number of IgG+ myofibers per 10 µm² and percent areas of replacement fibrosis identified by fibronectin staining larger than a myofiber were quantified by an individual blinded to treatment using Adobe Photoshop CS6 as previously described (32, 51, 83).

Data analysis and statistics. Data are displayed as dot-plots with all biological replicates for a given experiment (black dots) or compilation of experiments (black and grey dots) displaying mean ± SEM, or bar-graphs showing mean ± SEM with biological replicates. Grubbs’s test was used to exclude outliers from the compiled skeletal muscle flow cytometry data and immunofluorescence data prior to analysis. A total of 11 outliers across all treatments and skeletal muscle gates, including densities and percentages, were removed from flow cytometric analysis. One outlier was removed from only the quadriceps fibronectin immunofluorescence data. The Brown-Forsythe ANOVA was used to determine if the standard deviations were significantly different (F ≤ 0.05). For reported P-values from the flow cytometry data, the ordinary one-way ANOVA was used with the Benjamini, Krieger, and Yekutieli (BKY) test correcting for the false discovery rate if standard deviations were not different. The Welch’s ANOVA with the BKY test were utilized if standard deviations were significantly different. For reported P-values from the immunofluorescence and ELISA data, the ANOVA tests were applied identically as the flow cytometry statistics, but the Dunnett’s test correcting for multiple comparisons was used instead of BKY. Testing for significance was performed in GraphPad Prism software version 9.3.1 (GraphPad Prism Software, San Diego, CA). Means were considered significantly different from each other if P ≤ 0.05.
Study approval. Protocols were approved by the Institutional Animal Care and Use Committee of the Ohio State University, comply with the laws of the United States of America, and abide by the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Author Contributions

ZMH - contributed to overall study design, performed all cell and protein isolations and flow cytometry experiments, analyzed all data, drafted the manuscript and prepared all figures

CG – performed treatment, dissections, staining and blinded quantification for diaphragm and quadriceps pathology

CPR- performed all bioinformatics analysis, wrote the methods and drafted figures and prepared tables for the RNA sequencing data

JL – maintained the mdx mouse colony, assisted with dissections, and performed the cytokine array and ELISA

ABP- homogenized and quantified samples and assisted with the ELISA assay

SSB – contributed to study design, oversight and analysis of flow cytometry and sorting experiments, edited the manuscript

FA- contributed to the study design, oversight and analysis of RNA sequencing, edited the manuscript

JARF – design and oversight of overall study implementation and analysis, edited the manuscript

Acknowledgements

This work was supported by the National Institutes of Health R01NS124681, R01AR072574 and T32HL134616 and P30CA016058 that partially supports the Flow
Cytometry Shared Resource. We thank Bryan McElwain from the Flow Cytometry Shared Resource for assistance.
References


Figures and Legends:

Figure 1: Cytokine and chemokine levels in spironolactone- and prednisolone-treated mdx skeletal muscles. (A) Proteome Profiler Cytokine Array immunoblots incubated with lysates from spironolactone (SPR)- and prednisolone (PRD)-treated 5.5-week-old mdx quadriceps compared to vehicle (VEH)-treated controls (5 mg of protein pooled from n=5 SPR, n=4 PRD, n=5 VEH). (B) Immunoblots incubated with lysates from spironolactone (SPR)- and prednisolone (PRD)-treated 5.5-week-old mdx diaphragms compared to vehicle (VEH)-treated controls (5 mg of protein). (C) Immunoblot pixel densitometry bar graph displayed as a ratio comparing cytokine and chemokine levels between spironolactone (SPR)- and vehicle (VEH)-treated mdx quadriceps and (D) mdx diaphragms. (E) Immunoblot pixel densitometry bar graph displayed as a ratio comparing cytokine and chemokine levels between prednisolone (PRD)- and vehicle (VEH)-treated mdx quadriceps and (F) mdx diaphragms. A trend-line (dashes) is placed at y = 1 on each bar graph to visualize upregulated and
downregulated cytokines and chemokines. (G) ELISA assay for IL-1β on soluble protein extracts from quadriceps muscles isolated from mdx mice treated for 2 weeks with VEH (n=5), SPR (n=5) or PRD (n=4) compared to untreated wild-type control (C57) (n=3). Statistics used are ANOVA with Dunnett test comparing each group with the vehicle (VEH) * ≤ 0.05.
Figure 2: Muscle leukocyte analysis in spironolactone- and prednisolone-treated mdx quadriceps. (A) Representative flow cytometry gating dot-plots displaying CD45+ CD11b+ myeloid cells, (B) CD45+ CD11b+ LY6G+ neutrophils, (C) CD45+ CD11b+ LY6G- CD64- LY6C^hi infiltrating monocytes, (D) CD45+ CD11b+ LY6G+ CD64+ macrophages, (E) CD45+ CD11b+ LY6G+ CD64+ CD206+ macrophages, (F) and CD45+ CD11b+ LY6G+ CD64+ F4/80^hi macrophages from spironolactone (SPR)- (n=13) and prednisolone (PRD)-treated (n=13) 4.5-week-old mdx quadriceps compared to vehicle (VEH) (n=12).
controls. (G) Quantification of myeloid cells, neutrophils (Nφ), infiltrating monocytes (Inf. MO), macrophages (MΦ), CD206+ macrophages (CD206+), and F4/80<sup>Hi</sup> macrophages (F4/80 Hi) represented as dot-plots for cells per milligram of muscle (Cells/mg) and (H) bar graphs with individual data points as percentages of total CD45<sup>+</sup> leukocytes (%CD45<sup>+</sup>), CD45<sup>+</sup> CD11b<sup>+</sup> myeloid cells (%CD45<sup>+</sup> CD11b<sup>+</sup>) or macrophages (%CD45<sup>+</sup> CD11b<sup>+</sup> LY6G<sup>-</sup> CD64<sup>+</sup>) comparing spironolactone (SPR)- and prednisolone (PRD)-treated mice to vehicle (VEH) controls. Experimental replicates are denoted by black and grey dots within the graphs. Statistics used are ANOVA with the Benjamini, Krieger, and Yekutieli test * = P ≤ 0.05.
Figure 3: Muscle leukocyte analysis in spironolactone- and prednisolone-treated mdx diaphragms. (A) Representative flow cytometry gating dot-plots displaying CD45+CD11b+ myeloid cells, (B) CD45+CD11b+LY6G+ neutrophils, (C) CD45+CD11b+LY6G-.
CD64⁺ LY6C⁺ infiltrating monocytes, (D) CD45⁺ CD11b⁺ LY6G⁻ CD64⁺ macrophages, (E) CD45⁺ CD11b⁺ LY6G⁻ CD64⁺ CD206⁺ macrophages, (F) and CD45⁺ CD11b⁺ LY6G⁻ CD64⁺ F4/80Hi macrophages from spironolactone (SPR)- and prednisolone (PRD)-treated 4.5-week-old mdx diaphragms compared to vehicle (VEH) controls. n=6 replicates per group pooled from 2 mice each were used. (G) Quantification of myeloid cells, neutrophils (Nφ), infiltrating monocytes (Inf. MO), macrophages (MΦ), CD206⁺ macrophages (CD206+), and F4/80Hi macrophages (F4/80 Hi) represented as dot-plots for cells per milligram of muscle (Cells/mg) and (H) bar graphs with individual data points as percentages of total CD45⁺ leukocytes (%CD45⁺), CD45⁺ CD11b⁺ myeloid cells (%CD45⁺ CD11b⁺) or macrophages (%CD45⁺ CD11b⁺ LY6G⁻ CD64⁺) comparing spironolactone (SPR)- and prednisolone (PRD)-treated mice to vehicle (VEH) controls. Experimental replicates are denoted by black and grey dots within the graphs. Statistics used are ANOVA with the Benjamini, Krieger, and Yekutieli test * = P ≤ 0.05.
Figure 4: Principal component analysis (PCA), overview of differentially expressed genes, and biological process gene ontology analysis of sequenced RNA from spironolactone- and prednisolone-treated *mdx* quadriceps' myeloid cells. (A) Principal component analysis reveals three distinct groupings based on treatment condition. n=3 replicates pooled from 3 mice each were used for each group. (B) Heatmap of all 896 genes that are differentially expressed between either prednisolone treatment vs vehicle, or spironolactone treatment vs. vehicle. (C) Overlap
analysis reveals 53 genes which are differentially expressed in both prednisolone vs. vehicle and spironolactone vs. vehicle. Prednisolone and spironolactone treatments yield 633 and 210 gene respectively which are uniquely differentially expressed in those treatment conditions vs. vehicle. (D) Gene ontology analysis for biological processes.
Figure 5: Analysis of overlapped, differentially expressed genes in sequenced RNA from spironolactone- and prednisolone-treated mdx quadriceps’ myeloid cells. (A) Heatmap of the 53 genes which are differentially expressed in both prednisolone treatment and spironolactone treatment conditions. Of the commonly differentially expressed genes, 45 genes are regulated in the same direction vs. vehicle, while 8 are regulated in the opposite direction vs. vehicle. Genes of interest are outlined in red boxes. (B) Transcripts per million of differentially expressed genes implicated in DMD pathology: Fn1, Hif1a, Thbs1, Fos, Dusp1, Ccl3, Vegfa, Per1, and Ccl4. Significant differences are from Benjamini-Hochberg adjusted P-values following DESeq2 analysis * = P \leq 0.05.
Figure 6: Histology, myofiber degeneration, and fibrosis in spironolactone and prednisolone-treated mdx diaphragms and quadriceps. (A) Overall pathology (H&E) and staining for ongoing degenerating myofibers (IgG – green); and fibronectin (red) of diaphragm muscle sections from 4.5-week-old mdx mice treated with vehicle (VEH)-, spironolactone (SPR)- or prednisolone (PRD) for 1 week shows active degeneration, inflammation and fibrosis in dystrophic muscles. (B) Quantification of IgG+ fibers per 10 µm$^2$ and (C) percent area of fibronectin staining in diaphragm shows improved dystrophic pathology with spironolactone, but not prednisolone after 1 week of treatment. (n=7 SPR, n=7 PRD, n=8 VEH) (D) Staining for overall pathology (H&E), fibrosis (fibronectin – red) and colocalization of fibroblasts (vimentin – red) and myeloid immune cells (CD11b – green) at sites of injury in quadriceps muscle sections from 5.5-week-old mdx mice treated for 2 weeks with vehicle, spironolactone or prednisolone. (E) Quantification of fibronectin staining in quadriceps muscle sections shows increased fibrosis with prednisolone treatment. (n=6 SPR, n=6 PRD, n=6 VEH). Bar = 100 µm. Statistics used are ANOVA with Dunnett test comparing each group with the vehicle (VEH) * ≤ 0.05 and ** ≤ 0.01.
Table 1: Spironolactone and prednisolone-treated *mdx* skeletal muscle chemokine quantification

<table>
<thead>
<tr>
<th>Relative Chemokine Levels</th>
<th>Eotaxin</th>
<th>CCL2</th>
<th>CCL3</th>
<th>CCL4</th>
<th>CCL5</th>
<th>CCL12</th>
<th>CXCL1</th>
<th>CXCL2</th>
<th>CXCL9</th>
<th>CXCL10</th>
<th>CXCL11</th>
<th>CXCL13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coordinate</td>
<td>A6</td>
<td>C5</td>
<td>C8</td>
<td>C9</td>
<td>C11</td>
<td>C6</td>
<td>C3</td>
<td>C10</td>
<td>C14</td>
<td>C1</td>
<td>C2</td>
<td>A1</td>
</tr>
<tr>
<td>SPR/VEH QUAD</td>
<td>= = =</td>
<td>↓32%</td>
<td>↓74%</td>
<td>↓52%</td>
<td>↓16%</td>
<td>↓51%</td>
<td>↓75%</td>
<td>↓93%</td>
<td>↓41%</td>
<td>↓42%</td>
<td>↓55%</td>
<td></td>
</tr>
<tr>
<td>PRD/VEH QUAD</td>
<td>↓66%</td>
<td>↓27%</td>
<td>↓5%</td>
<td>↓88%</td>
<td>↓77%</td>
<td>↓77%</td>
<td>↓78%</td>
<td>↓98%</td>
<td>↓87%</td>
<td>↓74%</td>
<td>↓58%</td>
<td>↑2.0x</td>
</tr>
<tr>
<td>SPR/VEH DIA</td>
<td>↑1.1x</td>
<td>↑1.2x</td>
<td>11.3x</td>
<td>11.2x</td>
<td>↓6%</td>
<td>↑1.6x</td>
<td>↓22%</td>
<td>11.3x</td>
<td>↑1.1x</td>
<td>↑28%</td>
<td>= = =</td>
<td></td>
</tr>
<tr>
<td>PRD/VEH DIA</td>
<td>↑1.5x</td>
<td>↑1.2x</td>
<td>12.8x</td>
<td>12.3x</td>
<td>↓6%</td>
<td>↑1.8x</td>
<td>16.4x</td>
<td>↑1.3x</td>
<td>↓2%</td>
<td>↑2.7x</td>
<td>↑1.1x</td>
<td></td>
</tr>
</tbody>
</table>

Changes in chemokine levels quantified using pixel densitometry from immunoblots displayed in Figure 1A, 1B, listed with coordinates that correspond to the location on the blots. Down and up arrows indicate percentage decrease or fold increase, respectively. Equivalent levels of chemokines are depicted by triple equal signs (= = =).
Table 2: Spironolactone and prednisolone-treated *mdx* skeletal muscle cytokine quantification

<table>
<thead>
<tr>
<th>Relative Cytokine Levels</th>
<th>IFNγ</th>
<th>TNFα</th>
<th>IL-1α</th>
<th>IL-1β</th>
<th>IL-2</th>
<th>IL-4</th>
<th>IL-10</th>
<th>IL-12</th>
<th>IL-17</th>
<th>TREM-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coordinate</td>
<td>A8</td>
<td>D3</td>
<td>A9</td>
<td>A10</td>
<td>A12</td>
<td>B2</td>
<td>B6</td>
<td>B8</td>
<td>B10</td>
<td>D4</td>
</tr>
<tr>
<td>SPR/VEH QUAD</td>
<td>↑1.2x</td>
<td>↓27%</td>
<td>↓12%</td>
<td>↓78%</td>
<td>↓50%</td>
<td>↓62%</td>
<td>↓38%</td>
<td>↓37%</td>
<td>↓45%</td>
<td>↓83%</td>
</tr>
<tr>
<td>PRD/VEH QUAD</td>
<td>↑1.2x</td>
<td>↓49%</td>
<td>↓75%</td>
<td>↓94%</td>
<td>↓33%</td>
<td>↓65%</td>
<td>↓83%</td>
<td>↓64%</td>
<td>↓76%</td>
<td>↓93%</td>
</tr>
<tr>
<td>SPR/VEH DIA</td>
<td>↓8%</td>
<td>↑1.1x</td>
<td>↑1.7x</td>
<td>↓15%</td>
<td>↓6%</td>
<td>↓35%</td>
<td>↓10%</td>
<td>↑1.9x</td>
<td>↓11%</td>
<td>↑1.8x</td>
</tr>
<tr>
<td>PRD/VEH DIA</td>
<td>↑3.4x</td>
<td>↑6.2x</td>
<td>↑1.4x</td>
<td>↑2.8x</td>
<td>↑2.0x</td>
<td>↑2.2x</td>
<td>↑1.5x</td>
<td>↑3.0x</td>
<td>↑4.9x</td>
<td>↑3.8x</td>
</tr>
</tbody>
</table>

Changes in cytokine levels quantified using pixel densitometry from immunoblots displayed in Figure 1A, 1B, listed with coordinates that correspond to the location on the blots. Down and up arrows indicate percentage decrease or fold increase, respectively.